SCHEMBL13775378

SCHEMBL13775378

CCOC(=O)CO[C@@H]1CCCN(C(=O)OCc2ccccc2)C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.49
NPC1 O15118 3/20 0.49
RAB9A P51151 2/20 0.49
PDE4B Q07343 1/20 0.48
CYP2C19 P33261 2/20 0.47
ALDH1A1 P00352 2/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
HTT P42858 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
TMEM97 Q5BJF2 2/20 0.44
SIGMAR1 Q99720 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
BCL9 O00512 1/20 0.44
CTNNB1 P35222 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
JAK2 O60674 1/20 0.44
JAK1 P23458 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29849138 0.93 SMN1; SMN2 (0.54) SMN1; SMN2NPC1RAB9APDE4BCYP2C19
SCHEMBL30556410 0.93 SMN1; SMN2 (0.54) SMN1; SMN2NPC1RAB9APDE4BCYP2C19
SCHEMBL29849351 0.93 SMN1; SMN2 (0.54) SMN1; SMN2NPC1RAB9APDE4BCYP2C19
SCHEMBL29333079 0.90 SMN1; SMN2 (0.54) SMN1; SMN2NPC1RAB9APDE4BCYP2C19
SCHEMBL31255559 0.89 SMN1; SMN2 (0.49) SMN1; SMN2NPC1RAB9ACYP2C19HTT
SCHEMBL5503589 0.88 SMN1; SMN2 (0.54) SMN1; SMN2NPC1RAB9APDE4BCYP2C19
SCHEMBL13775377 0.88 SMN1; SMN2 (0.54) SMN1; SMN2NPC1RAB9APDE4BCYP2C19
SCHEMBL28809437 0.87 SMN1; SMN2 (0.47) SMN1; SMN2NPC1RAB9APDE4BCYP2C19
SCHEMBL7398151 0.87 SMN1; SMN2 (0.47) SMN1; SMN2NPC1RAB9APDE4BCYP2C19
SCHEMBL2009867 0.86 SMN1; SMN2 (0.60) SMN1; SMN2NPC1RAB9ACYP2C19CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181942-A1 TRICYCLIC COMPOUNDS FDFT1, COASY, HMGCR SMN1; SMN2 4445/4885NPC1 187/4885RAB9A 4041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.